MRK Merck & Co. (MRK) Q3 FY25 earnings call
Merck delivered solid Q3 FY25 performance, driven by oncology strength and new product launches, reinforcing confidence in its science-led strategy. The company is making significant investments in its robust pipeline, with approximately 80 Phase III trials underway, and is committed to disciplined business development to fuel future growth. Discussions with the US administration on healthcare policy are ongoing, with an optimistic outlook for constructive outcomes.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
MRK operating KPIs by quarter
| KPI | Dec 2024 Q4 FY24 | Mar 2025 Q1 FY25 | This call Sep 2025 Q3 FY25 | Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | Change vs prior quarter |
|---|---|---|---|---|---|---|
| Patients WINREVAIR - US | ~1,500Approximately 1,500 new patients in the US received a prescription, bringing the total number of new patients prescribed to approximately 5,200 since launch.Source: earnings call transcript | 1,400+In the US, more than 1,400 new patients received a prescription during the quarter.Source: earnings call transcript | ~1,500In the US, approximately 1,500 new patients received a prescription and over 24,000 total prescriptions were dispensed in the quarter, a testament to the continued strong demand for this important treatment option.Source: earnings call transcript | 1,500+In the US, more than 1,500 new patients received a prescription and over 27,000 total prescriptions were dispensed.Source: earnings call transcript | 1,600+In the US, we continued to see steady progress with more than 1,600 new patients having received a prescription and an increase in usage by patients with background therapies do not include a prostacyclin.Source: earnings call transcript | — |
| Prescriptions filled WINREVAIR - US | — | — | 24K+In the US, approximately 1,500 new patients received a prescription and over 24,000 total prescriptions were dispensed in the quarter, a testament to the continued strong demand for this important treatment option.Source: earnings call transcript | 27K+In the US, more than 1,500 new patients received a prescription and over 27,000 total prescriptions were dispensed.Source: earnings call transcript | — | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.